METASTATIC MELANOMA

This study tests whether giving a lower, less frequent dose of the cancer drug atezolizumab can still control tumors while causing fewer side effects. About 30 adults with advanced lung, liver, skin, or sarcoma cancers will receive the drug alone or with other treatments. Researc…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…

This study tests two drugs, cabozantinib and nivolumab, in 150 people with advanced melanoma or head and neck cancer that hasn't responded to prior immunotherapy. The goal is to see if the combination shrinks tumors and how quickly doctors can use tumor biomarkers to sort patient…

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or come back. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified to produce a protein (IL15) t…

This early-phase trial tests whether injecting a flu vaccine directly into melanoma tumors can shrink them or slow the cancer's spread. About 36 adults with stage I-IV melanoma will receive the injections. The main goals are to check safety and find the best dose.

This program offers a special cell therapy called AMTAGVI to people with advanced melanoma that cannot be removed by surgery or has spread. The treatment is made from the patient's own immune cells and is normally only given when it meets strict quality standards. Here, patients …

This study tests a new treatment called [212Pb]VMT01, which delivers targeted radiation to melanoma cells. It is for people with advanced melanoma that has not responded to prior therapies. The trial will evaluate safety and effectiveness when given alone or with the immunotherap…

This study tests whether giving precise, high-dose radiation to a few growing spots of melanoma can delay overall cancer progression. About 52 adults whose cancer has started to grow in up to 10 spots while on standard treatment will receive focused radiation to those spots. The …

This study tests a drug called avapritinib in people with advanced solid tumors that have spread and have specific gene changes (CKIT or PDGFRA mutations). The drug works by blocking enzymes that help cancer cells grow. The goal is to see if avapritinib can shrink or control thes…

This study tests a new oral drug called STC-15, either alone or combined with toripalimab, in people with advanced solid tumors or certain sarcomas (leiomyosarcoma and liposarcoma). The goal is to see if the treatment is safe and can shrink or control tumors. About 107 adults wit…

This early-phase study tests a combination of two ways to give the immunotherapy drug nivolumab: through a vein and directly into the fluid around the spine. It is for people with melanoma or lung cancer that has spread to the lining of the brain or spinal cord (leptomeningeal di…

This early-stage study tests a new treatment called Adze1.C, a virus designed to infect and kill cancer cells while also boosting the immune system. It is for adults with advanced melanoma that has not responded to standard therapies. The main goals are to check the treatment's s…

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…

This study tests a new treatment for advanced melanoma that has spread to the brain. It combines chemotherapy (temozolomide) with specially grown immune cells from a healthy donor (called NK cells). The goal is to see if this combination is safe and can shrink brain tumors. About…

This study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …

This study tests whether adding an experimental drug (GB1211) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced melanoma or head and neck cancer. About 92 participants will receive either the combination or a placebo plus pem…

This early-phase study tests whether specially trained natural killer (NK) cells, given with two immunotherapy drugs (nivolumab and relatlimab), are safe and can shrink tumors in people with advanced melanoma that stopped responding to standard checkpoint inhibitors. About 33 adu…

This study tests whether combining two drugs—pembrolizumab (an immunotherapy) and aldesleukin (a cytokine)—can shrink tumors in people with advanced melanoma or kidney cancer that has not responded to prior treatments. About 78 adults will receive the drugs through an IV during t…

This study tests two different drug combinations in people with BRAF-V600 mutant melanoma that has spread to the brain. One group gets a three-drug mix (encorafenib, binimetinib, and nivolumab), the other gets two immunotherapy drugs (ipilimumab and nivolumab). The goal is to see…

This early-stage trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes, or TILs) for people with advanced uveal melanoma (an eye cancer) or certain sarcomas (soft tissue cancers). About 30 participants will have their tumor removed, immune…

This study tests two drugs, binimetinib and encorafenib, in people with advanced melanoma that has spread to the brain. The drugs block enzymes that help cancer cells grow. The goal is to see if this combination can control the disease and improve survival. About 35 adults with a…

This study tests whether combining a personalized cell therapy (lifileucel) with an immunotherapy drug (pembrolizumab) works better than the drug alone for people with advanced melanoma that cannot be removed by surgery or has spread. About 670 adults with untreated melanoma will…

This early-stage trial tests a new drug (IOV-3001) combined with an immune cell therapy (lifileucel) in adults with advanced melanoma that has stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can help control the disease. About…

This study tests whether combining a liver-directed chemotherapy (HEPZATO KIT) with two immunotherapy drugs (nivolumab and relatlimab, together called Opdualag) is safe and effective for people with metastatic melanoma that has spread to the liver. About 15 participants who have …

This study tests if freezing part of a growing tumor (cryoablation) combined with two immunotherapy drugs (ipilimumab and nivolumab) can help control advanced melanoma that stopped responding to prior treatment. About 37 adults with unresectable melanoma will receive the combinat…

This study tests whether a blood test that measures tumor DNA (ctDNA) can help doctors decide when to add a third immunotherapy drug (ipilimumab) for people with advanced melanoma who are already taking two others (nivolumab and relatlimab). About 90 adults with advanced or metas…

This early-stage study is testing whether adding a drug called nilotinib to standard melanoma treatments (dabrafenib/trametinib or encorafenib/binimetinib) is safe and tolerable for patients. It is for adults whose advanced, BRAF-mutated melanoma has stopped responding to or prog…

This study is testing an experimental drug called mirdametinib in people with advanced melanoma that has a specific genetic change (an NF1 mutation) and has continued to grow despite previous immunotherapy. The main goals are to see if the drug is safe and if it can slow or stop …

This study tests whether giving radiation in three smaller doses (fractionated SRS) is better than a single large dose (standard SRS) for treating cancer that has spread to the brain. About 269 adults with certain cancers (like lung, breast, or melanoma) will be enrolled. The goa…

This study tests if a short bout of exercise right before immunotherapy (Nivolumab and Ipilimumab) can boost the immune system and improve treatment effectiveness in people with advanced melanoma. Researchers will check if this approach is practical for patients and whether it in…

This study looks at whether getting immunotherapy in the morning or afternoon changes how well it fights advanced or metastatic solid tumors. Researchers believe the body's internal clock (circadian rhythm) might affect immune response. About 160 adults with certain cancers like …

This study tests whether freezing bone tumors (cryoablation) before giving radiation therapy works better than radiation alone for reducing pain. About 40 adults with cancer that has spread to the bones will be enrolled. The goal is to see if the combination provides more complet…

This study looks at how immune cells called T cells change in people with advanced melanoma, lung, or other cancers during anti-PD-1 therapy. Researchers will measure specific markers in blood samples to see if they can predict treatment response or resistance. The goal is to und…

This study monitors patients who have already received at least one dose of Replimune's experimental cancer therapy (RPx) for up to 5 years. The goal is to identify any delayed side effects or infections related to the treatment. No new drugs are given—participants simply provide…

This study aims to create an artificial intelligence tool that analyzes photos of skin damage around a melanoma scar to predict whether a patient will respond to anti-PD-1 immunotherapy. Researchers will enroll 700 adults with advanced melanoma or other skin cancers. The goal is …

This study looks at how effective first-line immunotherapy is for people with metastatic melanoma in Slovenia. Researchers will track treatment response and safety, and analyze blood, stool, and body fluids to find markers that predict who benefits most. The goal is to improve pe…

This study is looking at how effective immunotherapy is as a first treatment for metastatic melanoma that has spread. Researchers will check if a marker called PD-L1, found in tumors and blood, can help predict who will respond well. About 100 adults with advanced melanoma will t…